Lv41
510 积分 2022-05-12 加入
Lp(a): A Rapidly Evolving Therapeutic Landscape
1小时前
待确认
Oxidized phospholipids in cardiovascular disease
1小时前
已完结
Therapeutic advances in the Lp(a) battle: what do we know and what are the most awaited novelties in the field ?
2小时前
已完结
Managing Dyslipidemia in Chronic Kidney Disease: Implications for Cardiovascular and Renal Risk
3小时前
已完结
Non-peptide, once-per-day oral orforglipron to compete with established peptide-based, injectable GLP-1 receptor agonists
3小时前
已完结
Glucose-dependent insulinotropic peptide and beyond: co-agonist innovations in the treatment of metabolic diseases
3小时前
已完结
Multiscale biased chemical space remodeling for developing APLNR agonists with anti-HFpEF efficacy
4小时前
求助中
The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron
5天前
已完结
Potential of Edaravone Dexborneol in the treatment of cerebral ischemia: focus on cell death-related signaling pathways
6天前
已完结
Elabela/Toddler and apelin bind differently to the apelin receptor
12天前
已完结
皖公网安备34019202002308
